BR9509997A - Antagonista de taquiquinina - Google Patents
Antagonista de taquiquininaInfo
- Publication number
- BR9509997A BR9509997A BR9509997A BR9509997A BR9509997A BR 9509997 A BR9509997 A BR 9509997A BR 9509997 A BR9509997 A BR 9509997A BR 9509997 A BR9509997 A BR 9509997A BR 9509997 A BR9509997 A BR 9509997A
- Authority
- BR
- Brazil
- Prior art keywords
- tachykinin antagonist
- tachykinin
- antagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9425085.9A GB9425085D0 (en) | 1994-12-13 | 1994-12-13 | Organic compounds |
| GBGB9426016.3A GB9426016D0 (en) | 1994-12-22 | 1994-12-22 | Organic compounds |
| PCT/EP1995/004910 WO1996018643A1 (en) | 1994-12-13 | 1995-12-12 | Tachykinin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9509997A true BR9509997A (pt) | 1997-12-30 |
Family
ID=26306161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9509997A BR9509997A (pt) | 1994-12-13 | 1995-12-12 | Antagonista de taquiquinina |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0797583A1 (pt) |
| JP (1) | JPH10511935A (pt) |
| AR (1) | AR001332A1 (pt) |
| AU (1) | AU4343796A (pt) |
| BR (1) | BR9509997A (pt) |
| CA (1) | CA2204130A1 (pt) |
| CO (1) | CO4700289A1 (pt) |
| CZ (1) | CZ179097A3 (pt) |
| FI (1) | FI971685A7 (pt) |
| HU (1) | HUT77002A (pt) |
| IL (1) | IL116323A0 (pt) |
| NO (1) | NO972526L (pt) |
| PE (1) | PE38997A1 (pt) |
| PL (1) | PL320217A1 (pt) |
| SK (1) | SK74697A3 (pt) |
| TR (1) | TR199501568A2 (pt) |
| WO (1) | WO1996018643A1 (pt) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69736390T2 (de) * | 1996-10-07 | 2007-07-26 | Merck Sharp & Dohme Ltd., Hoddesdon | Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum |
| US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| WO2000048623A1 (en) | 1999-02-18 | 2000-08-24 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives as growth hormone secretagogues |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| WO2001032625A1 (en) | 1999-11-03 | 2001-05-10 | Du Pont Pharmaceuticals Company | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| JP5132864B2 (ja) | 2000-07-11 | 2013-01-30 | アルバニー モレキュラー リサーチ， インコーポレイテッド | ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法 |
| AU2005274927B2 (en) | 2004-07-15 | 2011-11-03 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
| KR101594898B1 (ko) | 2005-07-15 | 2016-02-18 | 알바니 몰레큘라 리써치, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| EA016079B1 (ru) | 2007-01-10 | 2012-01-30 | Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа | Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp) |
| JP2010516731A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物 |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| CN102014631A (zh) | 2008-03-03 | 2011-04-13 | 泰格尔医药科技公司 | 酪氨酸激酶抑制剂 |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| CN102458123A (zh) | 2009-05-12 | 2012-05-16 | 阿尔巴尼分子研究公司 | 芳基、杂芳基和杂环取代的四氢异喹啉及其用途 |
| WO2010132487A1 (en) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
| US8802696B2 (en) | 2009-05-12 | 2014-08-12 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof |
| JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | ｐ５３活性を増大する置換ピペリジン及びその使用 |
| EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| AU2011285909B2 (en) | 2010-08-02 | 2016-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| EP2699567A1 (en) | 2011-04-21 | 2014-02-26 | Merck Sharp & Dohme Corp. | Insulin-like growth factor-1 receptor inhibitors |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP3358013B1 (en) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| KR20150060724A (ko) | 2012-09-28 | 2015-06-03 | 머크 샤프 앤드 돔 코포레이션 | Erk 억제제인 신규 화합물 |
| DK2925888T3 (en) | 2012-11-28 | 2017-12-18 | Merck Sharp & Dohme | COMPOSITIONS AND METHODS OF CANCER TREATMENT |
| EP2935263B1 (en) | 2012-12-20 | 2018-12-05 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| BR112021002267A8 (pt) | 2018-08-07 | 2023-02-07 | Merck Sharp & Dohme | Inibidores de prmt5 |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
| JPH05186498A (ja) * | 1991-12-27 | 1993-07-27 | Japan Tobacco Inc | プロリン誘導体 |
-
1995
- 1995-12-11 PE PE1995286859A patent/PE38997A1/es not_active Application Discontinuation
- 1995-12-11 IL IL11632395A patent/IL116323A0/xx unknown
- 1995-12-12 CZ CZ971790A patent/CZ179097A3/cs unknown
- 1995-12-12 CA CA002204130A patent/CA2204130A1/en not_active Abandoned
- 1995-12-12 HU HU9701897A patent/HUT77002A/hu unknown
- 1995-12-12 PL PL95320217A patent/PL320217A1/xx unknown
- 1995-12-12 JP JP8518261A patent/JPH10511935A/ja active Pending
- 1995-12-12 SK SK746-97A patent/SK74697A3/sk unknown
- 1995-12-12 EP EP95942131A patent/EP0797583A1/en not_active Withdrawn
- 1995-12-12 FI FI971685A patent/FI971685A7/fi not_active Application Discontinuation
- 1995-12-12 BR BR9509997A patent/BR9509997A/pt not_active Application Discontinuation
- 1995-12-12 AU AU43437/96A patent/AU4343796A/en not_active Abandoned
- 1995-12-12 WO PCT/EP1995/004910 patent/WO1996018643A1/en not_active Ceased
- 1995-12-12 CO CO95058767A patent/CO4700289A1/es unknown
- 1995-12-13 AR AR33458995A patent/AR001332A1/es unknown
- 1995-12-13 TR TR95/01568A patent/TR199501568A2/xx unknown
-
1997
- 1997-06-03 NO NO972526A patent/NO972526L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ179097A3 (en) | 1997-10-15 |
| FI971685L (fi) | 1997-08-13 |
| AR001332A1 (es) | 1997-10-22 |
| FI971685A0 (fi) | 1997-04-18 |
| CO4700289A1 (es) | 1998-12-29 |
| PL320217A1 (en) | 1997-09-15 |
| NO972526D0 (no) | 1997-06-03 |
| SK74697A3 (en) | 1997-11-05 |
| EP0797583A1 (en) | 1997-10-01 |
| MX9703957A (es) | 1997-09-30 |
| HUT77002A (hu) | 1998-03-02 |
| WO1996018643A1 (en) | 1996-06-20 |
| NO972526L (no) | 1997-06-03 |
| IL116323A0 (en) | 1996-03-31 |
| FI971685A7 (fi) | 1997-08-13 |
| PE38997A1 (es) | 1997-10-02 |
| CA2204130A1 (en) | 1996-06-20 |
| AU4343796A (en) | 1996-07-03 |
| TR199501568A2 (tr) | 1996-07-21 |
| JPH10511935A (ja) | 1998-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI971685L (fi) | Takykiniini-antagonisteja | |
| FI970523A7 (fi) | (Atsetidin-1-yylialkyyli)laktaamit takykiniiniantagonisteina | |
| EE9600186A (et) | Neurokiniini (tahhüülkiniini) antagonistid | |
| PT805813E (pt) | Antagonistas de vasopressina triciclicos | |
| FI954008A7 (fi) | Substituoituja bifenyyli-isoksatsolisulfoniamideja | |
| FI951908A7 (fi) | Substituoituja pyridyylipyratsoleja | |
| FI955927A7 (fi) | Substituoidut 1H-imidatsolit | |
| DE69534718D1 (de) | Substituierte 9-alkyladenine | |
| DK0824098T3 (da) | 4-Hydroxy-piperidinderivater | |
| FI960516L (fi) | Substituoituja bifenyylisulfonamidiendoteliiniantagonisteja | |
| ATE232526T1 (de) | 3-azetidinylalkylpiperidine oder -pyrrolidine als tachykinin antagonisten | |
| NO964172L (no) | Virvelindusert vibrasjonssperre | |
| DE69732715D1 (de) | Tachykinin antagoniste | |
| DE69735811D1 (de) | Piperazinoderivate als neurokinin-antagonisten | |
| NO975541D0 (no) | 4-hydroksy-piperidinderivater | |
| BR9503042A (pt) | Composto de polialquilpiperidina | |
| BR9509559A (pt) | Azolilulsolfonilfeniluracilas substituídas | |
| DE59602637D1 (de) | Heftvorrichtung | |
| KR950027351U (ko) | 반목 항타장치 | |
| DE59510274D1 (de) | Substituierte biphenyloxazoline | |
| KR970702876A (ko) | 뉴로키닌 길항제(Neurokinine (tachykinine) antagonists) | |
| DK0964867T3 (da) | Tachykininantagonister | |
| KR950033383U (ko) | 가드레일 | |
| IT1286743B1 (it) | Barriera antiacustica | |
| PT9246T (pt) | Barreira antiencandeamento polivalente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law |